Henry Meds vs Mochi Health
Two GLP-1 desks, one scoreboard. We put Henry Meds and Mochi Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
Henry Meds
The verdict
Henry Meds takes this head-to-head.
Henry Meds scores 84 to 81 on our six-factor Brief Score — A flat-fee compounded pioneer — simple model, but its price has drifted to the higher end of our board.
That doesn't make Mochi Health a bad call — it's best for readers in its served states who want a known consumer brand with a coaching bent. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Henry Meds | Mochi Health | |
|---|---|---|
| Brief Score | 84/100 (B) | 81/100 (B−) |
| Semaglutide | $249/mo | $138/mo |
| Tirzepatide | $349/mo | $238/mo |
| Coverage | Multi-state | 15 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Risingprice rising | Stableprice stable |
Henry Meds: Flat-fee pioneer, but its line has drifted to the higher end of the tracker.
Mochi Health: $138 sema / $238 tirz; footprint capped near 15 states.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.